medRxiv · 2021 · 13 citations · 15 references
Veterinary MedicineImmunologyInfectious DiseasesClinical ImmunologyImmunology Of Infectious DiseasesVaccinologyDiagnostic ImmunologyImmunization PracticeVaccinationVaccine EffectivenessViral VaccinesAntibody ImmunogenicityAntibody TiteringClinical Laboratory EvaluationCoronavirus DiagnosticsCoronavirus VaccinesSars-cov-2 InfectionSerological IdentificationViral Antigen Detection
Abstract The COVID-19 pandemic continues to impose a significant burden on global health infrastructure. While identification and containment of new cases remains important, laboratories must now pivot and consider assessment of SARS-CoV-2 immunity in the setting of the recent availability of multiple COVID-19 vaccines. Here we have utilized the latest Abbott Alinity semi-quantitative IgM and quantitative IgG spike protein (SP) serology assays (IgM SP and IgG SP ) in combination with Abbott Alinity IgG nucleocapsid (NC) antibody test (IgG NC ) to assess antibody responses in a cohort of 1236 unique participants comprised of naïve, SARS-CoV-2 infected, and vaccinated (including both naïve and recovered) individuals. The IgM SP and IgG SP assays were highly specific (100%) with no cross-reactivity to archived samples recovered prior to the emergence of SARS-CoV-2, including those from individuals with seasonal coronavirus infections. Clinical sensitivity was 96% after 15 days for both IgM SP and IgG SP assays individually. When considered together, the sensitivity was 100%. A combination of NC- and SP-specific serologic assays clearly differentiated naïve, SARS-CoV-2-infected, and vaccine-related immune responses. Vaccination resulted in a significant increase in IgG SP and IgM SP titers, with a major rise in IgG SP following the booster (second) dose in the naïve group. In contrast, SARS-CoV-2 recovered individuals had several fold higher IgG SP responses than naïve following the primary dose, with a comparatively dampened response following the booster. This work illustrates the strong clinical performance of these new serological assays and their utility in evaluating and distinguishing serological responses to infection and vaccination.
15
Virological assessment of hospitalized patients with COVID-2019
Roman Wölfel, Victor M. Corman, Wolfgang Guggemos et al. · Nature · 2020 · 7.2K citations · Full text
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Lisa A. Jackson, Evan J. Anderson, Nadine Rouphael et al. · New England Journal of Medicine · 2020 · 3.5K citations · Full text
Antibody responses to SARS-CoV-2 in patients with COVID-19
Quanxin Long, Bai-Zhong Liu, Haijun Deng et al. · Nature Medicine · 2020 · 3.1K citations · Full text
Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection
Jennifer M. Dan, José Mateus, Yu Kato et al. · Science · 2021 · 3K citations · Full text
COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
Uğur Şahin, Alexander Muik, Evelyna Derhovanessian et al. · Nature · 2020 · 2K citations · Full text